

# Denis Fedyaev

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1905665/publications.pdf>

Version: 2024-02-01

12  
papers

16  
citations

2682572

2  
h-index

2272923

4  
g-index

12  
all docs

12  
docs citations

12  
times ranked

16  
citing authors

#	ARTICLE	IF	CITATIONS
1	Key business processes in healthcare and their readiness for digital transformation. Medical Technologies Assessment and Choice (Формирование готовности бизнес-процессов здравоохранения к цифровой трансформации. Медицинская оценка технологий и выбор) [1]. Farmakoekonomika, 2021, 13, 427-437.	0.4	2
2	Development of a method for calculation of demand for medical personnel in the healthcare of the Russian Federation, using a mathematical model. Farmakoekonomika, 2021, 13, 427-437.	1.2	0
3	Review of foreign experience in the implementation of eHealth. Farmakoekonomika, 2021, 14, 63-71.	1.2	3
4	Analysis of demographic, social and economic impacts of proximal femur fracture's surgical treatment for geriatric patients in Russia. Russian Journal of Geriatric Medicine, 2021, , 201-210.	0.6	0
5	Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation. Farmakoekonomika, 2020, 12, 300-308.	1.2	2
6	The review of the foreign experience on the financing of innovative medical technologies. Farmakoekonomika, 2020, 13, 316-323.	1.2	1
7	The evaluation of the balance of standard rates within the program on state guarantees to deliver free medical care to the citizens of the Russian Federation. Farmakoekonomika, 2020, 13, 283-290.	1.2	0
8	Organization and financial support of healthcare for public employees in the Russian Federation: a review of departmental health services in the Ministry of Defense. Farmakoekonomika, 2019, 11, 81-91.	1.2	0
9	Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan. Farmakoekonomika, 2019, 12, 14-26.	1.2	4
10	Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available. Farmakoekonomika, 2019, 12, 115-124.	1.2	2
11	Overview of the existing opportunities and limitations of the state guarantees program for provision of free medical care to citizens. Farmakoekonomika, 2019, 12, 221-229.	1.2	2
12	Diagnosis-related groups and payments for the treatment of malignant neoplasms in the model of 2019. Farmakoekonomika, 2019, 12, 169-177.	1.2	0